CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity
Ramin Salehi‐Rad(University of California, Los Angeles), Steven M. Dubinett(University of California, Los Angeles), Camelia Dumitras(University of California, Los Angeles), Tian-hao Zhang(University of California, Los Angeles), Maryam Shabihkhani(University of California, Los Angeles), Manash K. Paul(University of California, Los Angeles), Stacy J. Park(University of California, Los Angeles), Raymond J. Lim(University of California, Los Angeles), William P. Crosson(University of California, Los Angeles), Michael S. Oh(Northwestern University), Bitta Kahangi(University of California, Los Angeles), Linh M. Tran(University of California, Los Angeles), Edward B. Garon(University of California, Los Angeles), Christopher S. Seet(University of California, Los Angeles), Kostyantyn Krysan(University of California, Los Angeles), Aaron Lisberg(APLA Health), Bin Liu(University of California, Los Angeles), Rui Li(University of California, Los Angeles), Jensen Abascal(University of California, Los Angeles), Zi Ling Huang(University of California, Los Angeles), Yushen Du(University of California, Los Angeles)
Cited by 30
Related Papers
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
|Nature Medicine|2010|338
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
|Nature|2021|211
Secondary Lymphoid Tissue Chemokine Mediates T Cell-Dependent Antitumor Responses In Vivo
|The Journal of Immunology|2000|202